| |
|
|
|
Xtalks, Online
2025-11-07
Older adults with neurological diseases are often underserved in clinical research due to disease complexity, biological variability and trial designs that fail to reflect their real-world needs. This webinar will explore how precision medicine can solve these challenges by sub-classifying complex conditions and aligning trial strategies with the biology and lived experience of aging populations.
The featured speakers will highlight how disease-specific biomarkers and recent advances in biomarker science are redefining patient populations in areas such as cognitive decline, movement disorders and ophthalmology. By focusing on sub-classification and related endpoints, clinical trials can be more precise in measuring outcomes and evaluating emerging therapies, including advanced modalities like cell and gene therapies.
A central theme of the webinar will be patient centricity. Older adults face distinct challenges in clinical trial participation, including mobility limitations, comorbidities and heightened sensitivity to treatment-related toxicity. These realities demand careful consideration of trial design, from simplifying protocols and reducing burden to adjusting dose levels and safety assessments through the lens of population science. By integrating patient needs with scientific rigor, precision medicine can close efficacy gaps and bring meaningful therapies to elderly populations who are often underrepresented in research.
Register for this webinar to learn how patient centricity enhances precision medicine for age-related neurological diseases.
Keywords: Aging, Biomarkers, Clinical Research, Clinical Trial Design, Clinical Trials, CNS, CRO, Drug Development, Elderly Patients, Neurological Disorder, Neurology, Ophthalmology, Patient Support, Patient-Centricity, Precision Medicine, Sites, Therapeutic Areas
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Panos Papanastasopoulos, Associate Medical Director, PPD clinical research business of Thermo Fisher Scientific
Debra Schaumberg, ScD, OD, MPH, Vice President & Global Head, Strategic Development and Global Head of Strategic Scientific Solutions for Ophthalmology; Chair, Research Leadership Council, PPD clinical research business of Thermo Fisher Scientific
John Hamlet, Executive Director, Neuroscience and Pillar Head for Movement, Neuroinflammatory, and Pain Disorders, PPD clinical research business of Thermo Fisher Scientific
Sabine Krofczik-Wilhelm, PhD, Executive Director and Pillar Head of Neurodegenerative and Psychiatry, PPD clinical research business of Thermo Fisher Scientific
Alberto Lledó, MD, PhD, Vice President and Therapeutic Area Head, Clinical Research Group, Neuroscience, PPD clinical research business of Thermo Fisher Scientific
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2025-11-07
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|